Europe Preclinical Imaging Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | USD 682,607.83 |
 CAGR |
% |
| Principais participantes do mercado |
Mercado europeu de imagiologia pré-clínica, por produto (sistemas e serviços), reagentes (reagentes de imagiologia ótica pré-clínica, reagentes de imagiologia nuclear pré-clínica, agentes de contraste de ressonância magnética pré-clínica, agentes de contraste de ultrassons pré-clínica -clínico e agentes de contraste de tomografia computorizada pré-clínica), aplicação (investigação e desenvolvimento, descoberta de fármacos , Biodistribuição, deteção de células cancerígenas, biomarcadores e outros), utilizador final (organização de investigação contratada, empresas farmacêuticas e de biotecnologia, institutos de investigação académicos e governamentais, centro de diagnóstico e outros) - Tendências e previsões do sector para 2030.
Análise e tamanho do mercado de imagens pré-clínicas da Europa
O mercado é a indústria envolvida no fornecimento de soluções e tecnologias de imagem para a realização de investigação e experimentação em animais (geralmente roedores) na fase pré-clínica de desenvolvimento de medicamentos e investigação médica. Estas técnicas de imagem são cruciais para avaliar a segurança e eficácia de potenciais candidatos a medicamentos e tratamentos médicos antes de avançarem para ensaios clínicos envolvendo seres humanos. A imagiologia pré-clínica permite aos investigadores e às empresas farmacêuticas avaliar os efeitos dos candidatos a medicamentos nos organismos vivos antes de passarem para testes em humanos. Isto ajuda a identificar possíveis problemas, a otimizar os regimes posológicos e a reduzir o risco de efeitos adversos em fases posteriores.
A Data Bridge Market Research analisa que o mercado europeu de imagiologia pré-clínica deverá atingir o valor de 682.607,83 mil dólares até 2030, com um CAGR de 5,9% durante o período de previsão.
Este relatório de mercado também abrange análises de preços e avanços tecnológicos em profundidade.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Anos históricos |
2021 (personalizável para 2015 - 2020) |
|
Unidades Quantitativas |
Receita em milhares de dólares, volumes em unidades, preços em dólares |
|
Segmentos cobertos |
Por produto (sistemas e serviços), reagente (reagentes de imagem ótica pré-clínica, reagentes de imagem nuclear pré-clínica, agentes de contraste pré-clínicos para RM, agentes de contraste pré-clínicos para ecografia e agentes de contraste pré-clínicos. clínicos para tomografia computorizada), aplicação (investigação e desenvolvimento, descoberta de fármacos, biodistribuição, Detecção de células cancerígenas, biomarcadores e outros), utilizador final (organização de investigação contratada, empresas farmacêuticas e de biotecnologia, institutos de investigação académicos e governamentais, centro de diagnóstico e outros) |
|
Países abrangidos |
Alemanha, França, Reino Unido, Itália, Espanha, Rússia, Turquia, Bélgica, Países Baixos, Suíça e resto da Europa |
|
Participantes do mercado abrangidos |
PerkinElmer Inc., FUJIFILM Visualsonics, Inc, Bruker, Hologic, Inc, Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics KK, Vieworks Co., Ltd, LI-COR, Inc., Aspect Imaging Ltd., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd, IVIM Technology Inc., MR Solutions, AI4R, Photon e entre outros |
Definição do mercado de imagens pré-clínicas da Europa
A imagiologia pré-clínica é a utilização de várias técnicas e tecnologias de imagem para visualizar e estudar processos biológicos, doenças e respostas a medicamentos em modelos animais antes de serem testados em humanos. Envolve a imagiologia não invasiva de animais, normalmente roedores, como ratinhos e ratos, para obter informações sobre os mecanismos subjacentes das doenças e avaliar a eficácia e segurança de possíveis terapias.
Dinâmica do mercado de imagiologia pré-clínica na Europa
Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:
Motoristas
- Aumento do avanço tecnológico no domínio da imagem
A imagem pré-clínica refere-se à utilização de várias modalidades de imagem para visualizar e estudar os processos biológicos em animais antes dos ensaios clínicos. Estes sistemas ajudam os investigadores a obter informações sobre os mecanismos das doenças, a avaliar potenciais candidatos a medicamentos e a monitorizar a eficácia do tratamento. O avanço tecnológico no campo da imagem está a desempenhar um papel crucial na condução do crescimento do mercado.
As modernas tecnologias de imagem, como a ressonância magnética (RM) de alta resolução, a tomografia microcomputadorizada (micro-CT) e a ecografia avançada fornecem aos investigadores imagens mais claras e detalhadas das estruturas biológicas.
A integração de sistemas de imagem multimodais é outro avanço no mercado de imagens pré-clínicas, uma vez que estes sistemas combinam múltiplas técnicas de imagem, como PET-CT ou PET-RM, para fornecer informações complementares e aumentar a precisão dos estudos pré-clínicos, que permite aos investigadores investigar múltiplos aspetos de uma doença ou tratamento em simultâneo, levando a resultados mais abrangentes e fiáveis.
Além disso, houve melhorias significativas na análise de imagens e nos algoritmos de processamento de dados. As ferramentas avançadas de software e os algoritmos de aprendizagem automática permitem aos investigadores extrair dados quantitativos de imagens, automatizar tarefas de processamento de imagens e melhorar a precisão e a eficiência da análise de dados. Estes avanços poupam tempo e aumentam a reprodutibilidade e a fiabilidade dos estudos pré-clínicos.
As técnicas de imagem de alta resolução, os sistemas de imagem multimodais e os algoritmos avançados de análise de imagem estão a melhorar as capacidades da imagem pré-clínica e a permitir aos investigadores obter insights mais profundos sobre os mecanismos das doenças. Assim, o avanço na tecnologia de imagem está a impulsionar o crescimento do mercado.
- Número crescente de investimentos e financiamento em investigação e desenvolvimento
O crescente número de investimentos e financiamento em investigação e desenvolvimento (I&D) é um motor significativo do crescimento do mercado. As organizações estão a alocar recursos substanciais para o avanço das tecnologias de imagem e para apoiar iniciativas de investigação inovadoras, à medida que a importância da imagem pré-clínica na descoberta e desenvolvimento de medicamentos se torna mais evidente.
Os investimentos e o financiamento em I&D permitem o desenvolvimento de novas modalidades e técnicas de imagiologia pré-clínica. Este apoio financeiro facilita a melhoria dos sistemas de imagem, software e hardware, levando a uma melhor qualidade, resolução e sensibilidade da imagem. Estes avanços permitem aos investigadores obter informações mais precisas e detalhadas sobre os processos biológicos, os mecanismos de doença e as respostas ao tratamento, impulsionando o crescimento do mercado de imagiologia pré-clínica.
Além disso, o financiamento e os investimentos em I&D também promovem a tradução da investigação de imagiologia pré-clínica em aplicações clínicas. Estudos pré-clínicos bem-sucedidos podem atrair mais investimento e parcerias, levando ao desenvolvimento de técnicas e tecnologias de imagem para uso humano. Esta expansão em aplicações de imagiologia clínica fortalece ainda mais o mercado de imagiologia pré-clínica.
Assim, o crescente número de investimentos e financiamento em investigação e desenvolvimento é um motor significativo do crescimento do mercado.
Oportunidade
- Aumento da adoção de sistemas de imagem para fins pré-clínicos
As indústrias farmacêutica e biotecnológica estão continuamente à procura de novos candidatos a medicamentos para satisfazer as necessidades médicas não satisfeitas. A imagiologia pré-clínica permite uma compreensão mais abrangente dos potenciais candidatos a medicamentos, visualizando os seus efeitos nos organismos vivos. Isto ajuda a identificar candidatos promissores e a eliminar aqueles com características desfavoráveis no início do processo de desenvolvimento de medicamentos, poupando tempo e recursos. A mudança para a medicina personalizada requer uma compreensão mais profunda das condições individuais dos doentes. A imagiologia pré-clínica pode ser utilizada para avaliar a heterogeneidade da doença e adaptar as abordagens de tratamento, levando a terapias mais eficazes.
As técnicas de imagiologia pré-clínica são geralmente não invasivas ou minimamente invasivas, o que é vantajoso tanto para os animais de investigação como para a precisão dos dados recolhidos. Esta natureza não invasiva permite estudos longitudinais, reduzindo a necessidade de sacrifício de animais em vários momentos.
Assim, a crescente adoção de sistemas de imagem para fins pré-clínicos pode dar uma oportunidade para o crescimento do mercado no período de previsão.
Restrição / Desafio
- Estrutura regulamentar rigorosa para aprovação de produtos
As entidades reguladoras de todo o mundo estabeleceram diretrizes e requisitos rigorosos para a aprovação de produtos de imagem pré-clínica, o que pode criar barreiras para as empresas no mercado e é um fator de restrição significativo para o crescimento do mercado.
As agências reguladoras, a Agência Europeia do Medicamento (EMA), implementaram normas rigorosas para a aprovação de produtos, de forma a garantir a segurança do doente e a eficácia dos produtos de imagem pré-clínica. Estas normas incluem frequentemente testes pré-clínicos extensivos, submissão de dados e adesão às diretrizes de Boas Práticas de Laboratório (BPL).
O processo regulamentar para produtos de imagem pré-clínicos é demorado e dispendioso. As empresas realizam estudos abrangentes para demonstrar a segurança e eficácia dos seus produtos, o que implica investimentos significativos em investigação e desenvolvimento. Além disso, o processo de submissão regulamentar requer uma extensa documentação, análise de dados e interação com as autoridades reguladoras, o que aumenta o tempo e os custos.
Além disso, os rigorosos requisitos regulamentares podem variar entre as diferentes regiões, criando desafios adicionais para as empresas que operam nos mercados europeus. As empresas devem navegar pelo complexo cenário de aprovações regulamentares em diferentes países, o que pode levar a atrasos no lançamento de produtos e ao aumento dos custos de conformidade.
Assim, o quadro regulamentar rigoroso para a aprovação de produtos é uma restrição significativa para o crescimento do mercado.
Âmbito do mercado de imagens pré-clínicas da Europa
O mercado europeu de imagiologia pré-clínica está segmentado em quatro segmentos notáveis baseados em produtos, reagentes, aplicação e utilizador final. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.
Produto
- Sistemas
- Serviços
Com base no produto, o mercado europeu de imagiologia pré-clínica está segmentado em sistemas e serviços.
Reagentes
- Reagentes de imagem óptica pré-clínica
- Reagentes de imagem nuclear pré-clínica
- Agentes de contraste pré-clínicos para ressonância magnética
- Agentes de contraste pré-clínicos para ecografia
- Agentes de contraste pré-clínicos para tomografia computorizada
Com base em reagentes, o mercado está segmentado em reagentes de imagem ótica pré-clínicos, reagentes de imagem nuclear pré-clínicos, agentes de contraste de ressonância magnética pré-clínicos, agentes de contraste de ultrassons pré-clínicos e agentes de contraste de tomografia computadorizada pré-clínicos.
Aplicação
- Investigação e Desenvolvimento
- Descoberta de fármacos
- Biodistribuição
- Detecção de células cancerígenas
- Biomarcadores
- Outros
Com base na aplicação, o mercado está segmentado em investigação e desenvolvimento, descoberta de fármacos, biodistribuição, deteção de células cancerígenas, biomarcadores, entre outros.
Utilizador final
- Organização de investigação contratada
- Empresas farmacêuticas e de biotecnologia
- Institutos de Investigação Académica e Governamental
- Centro de Diagnóstico
- Outros
Com base no utilizador final, o mercado está segmentado em organizações de investigação por contrato, empresas farmacêuticas e de biotecnologia, institutos de investigação académicos e governamentais, centro de diagnóstico, entre outros.
Análise/Insights Regionais: Mercado Europeu de Imagiologia Pré-clínica
O mercado europeu de imagiologia pré-clínica é analisado e os insights e tendências do tamanho do mercado são fornecidos por país, produto, reagentes, aplicação e utilizador final.
Os países abrangidos neste relatório de mercado são a Alemanha, França, Reino Unido, Itália, Espanha, Rússia, Turquia, Bélgica, Países Baixos, Suíça e resto da Europa.
Prevê-se que a Alemanha domine a região da Europa devido à crescente procura de dispositivos de imagem e aos avanços tecnológicos.
A secção do relatório sobre países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas, análise das cinco forças de Porter e estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas da América do Norte e do Sul e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, o impacto das tarifas domésticas e as rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Cenário competitivo e análise de ações: mercado europeu de imagiologia pré-clínica
O panorama competitivo do mercado europeu de imagiologia pré-clínica fornece detalhes dos concorrentes. Os detalhes incluídos incluem a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, novas iniciativas de mercado, presença na Europa, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, largura e amplitude do produto e domínio de aplicação. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.
Alguns dos principais players do mercado que operam no mercado europeu de imagiologia pré-clínica são a PerkinElmer Inc., FUJIFILM Visualsonics, Inc, Bruker, Hologic, Inc, Zeiss International, Agilent Technologies, Inc., Hamamatsu Photonics KK, Vieworks Co., Ltd , LI- COR, Inc., Aspect Imaging Ltd., Berthold Technologies GmbH & Co.KG, MILabs BV, Trifoil Imaging, Mediso Ltd, IVIM Technology Inc., MR Solutions, AI4R, Photon e entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE PRECLINICAL IMAGING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 MARKET END USER COVERAGE GRID
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FIRCES
4.3 STRATEGIC INITIATIVES
4.4 CONCLUSION
5 REGULATORY FRAMEWORK
5.1 REGULATORY SCENARIO IN EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING TECHNOLOGY ADVANCEMENT IN THE FIELD OF IMAGING
6.1.2 INCREASING NUMBER OF INVESTMENTS AND FUNDING IN RESEARCH AND DEVELOPMENT
6.1.3 INCREASING INCIDENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY FRAMEWORK FOR PRODUCT APPROVAL
6.2.2 HIGH INSTALLATION AND OPERATIONAL COST OF PRECLINICAL IMAGING SYSTEMS
6.3 OPPORTUNITIES
6.3.1 INCREASING ADOPTION OF IMAGING SYSTEMS FOR PRECLINICAL PURPOSES
6.3.2 GROWING DEMAND FOR NON-INVASIVE SMALL-ANIMAL IMAGING METHODS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS FOR THE EFFECTIVE UTILIZATION OF PRECLINICAL IMAGING SYSTEMS
6.4.2 INTEGRATION OF IMAGING DEVICES WITH OTHER TECHNOLOGIES
7 EUROPE PRECLINICAL IMAGING MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 SYSTEMS
7.2.1 OPTICAL IMAGING SYSTEMS
7.2.1.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS
7.2.1.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS
7.2.1.3 OPTICAL + X-RAY/OPTICAL + CT
7.2.2 PRECLINICAL NUCLEAR IMAGING SYSTEMS
7.2.2.1 MICRO-POSITRON EMISSION TOMOGRAPHY (PET) SYSTEMS
7.2.2.2 MICRO-SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) SYSTEMS
7.2.2.3 TRIPRODUCT (SPECT/PET/CT) SYSTEMS
7.2.3 MICRO-MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS
7.2.4 MICRO-COMPUTED TOMOGRAPHY (CT) SYSTEMS
7.2.5 MICRO-ULTRASOUND SYSTEMS
7.2.6 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS
7.2.7 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS
7.2.8 MAGNETIC RESONANCE SPECTROSCOPY IMAGING (MRSI)
7.3 SERVICES
8 EUROPE PRECLINICAL IMAGING MARKET, BY REAGENTS
8.1 OVERVIEW
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS
8.2.1 BIOLUMINESCENT IMAGING REAGENTS
8.2.2 FLUORESCENT IMAGING REAGENTS
8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS
8.3.1 PRECLINICAL PET TRACERS
8.3.2 PRECLINICAL SPECT PROBES
8.4 PRECLINICAL MRI CONTRAST AGENTS
8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.2 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS
8.4.3 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS
8.6 PRECLINICAL CT CONTRAST AGENTS
8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
8.6.3 GOLD NANOPARTICLES
8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS
9 EUROPE PRECLINICAL IMAGING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 RESEARCH AND DEVELOPMENT
9.3 DRUG DISCOVERY
9.4 BIO-DISTRIBUTION
9.5 CANCER CELL DETECTION
9.6 BIO-MARKERS
9.7 OTHERS
10 EUROPE PRECLINICAL IMAGING MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATION
10.3 PHARMACEUTICAL & BIOTECH COMPANIES
10.4 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
10.5 DIAGNOSTICS CENTER
10.6 OTHERS
11 EUROPE PRECLINICAL IMAGING MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 RUSSIA
11.1.7 TURKEY
11.1.8 BELGIUM
11.1.9 NETHERLANDS
11.1.10 SWITZERLAND
11.1.11 REST OF EUROPE
12 EUROPE PRECLINICAL IMAGING MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 PERKINELMER INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 FUJIFILM VISUALSONICS, INC
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 HOLOGIC, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BRUKER
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 PRODUCT PORTFOLIO
14.4.4 RECENT DEVELOPMENT
14.5 ZEISS INTERNATIONAL
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.6 ADVANCED MOLECULAR VISION, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENT
14.7 AGILENT TECHNOLOGIES, INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 AI4R
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 BERTHOLD TECHNOLOGIES GMBH & CO.KG
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 HAMAMATSU PHOTONICS K.K.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 IVIM TECHNOLOGY CORP.
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 LI-COR, INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 MEDISO LTD.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MILABS B.V.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MR SOLUTIONS
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 PHOTON ETC
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 TRIFOIL IMAGING
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 VIEWORKS CO., LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
TABLE 1 EUROPE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE PRECLINICAL IMAGING MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 13 GERMANY PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 14 GERMANY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 15 GERMANY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 16 GERMANY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 17 GERMANY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 18 GERMANY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 19 GERMANY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 20 GERMANY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 21 GERMANY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 22 GERMANY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 23 GERMANY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 24 GERMANY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 25 GERMANY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 26 GERMANY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 27 GERMANY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 28 GERMANY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 29 GERMANY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 30 GERMANY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 31 GERMANY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 32 GERMANY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 33 GERMANY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 34 GERMANY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 35 GERMANY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 36 GERMANY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 37 GERMANY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 38 GERMANY PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 39 GERMANY PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 40 FRANCE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 41 FRANCE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 42 FRANCE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 43 FRANCE SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 44 FRANCE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 45 FRANCE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 46 FRANCE OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 47 FRANCE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 48 FRANCE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 49 FRANCE PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 50 FRANCE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 51 FRANCE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 52 FRANCE PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 53 FRANCE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 54 FRANCE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 55 FRANCE PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 56 FRANCE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 57 FRANCE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 58 FRANCE PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 59 FRANCE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 60 FRANCE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 61 FRANCE PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 62 FRANCE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 63 FRANCE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 64 FRANCE PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 65 FRANCE PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 66 FRANCE PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 67 U.K. PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 68 U.K. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 69 U.K. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 70 U.K. SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 71 U.K. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 72 U.K. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 73 U.K. OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 74 U.K. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 75 U.K. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 76 U.K. PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 77 U.K. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 78 U.K. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 79 U.K. PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 80 U.K. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 81 U.K. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 82 U.K. PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 83 U.K. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 84 U.K. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 85 U.K. PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 86 U.K. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 87 U.K. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 88 U.K. PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 89 U.K. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 90 U.K. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 91 U.K. PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 92 U.K. PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 93 U.K. PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 94 ITALY PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 95 ITALY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 96 ITALY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 97 ITALY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 98 ITALY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 99 ITALY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 100 ITALY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 101 ITALY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 102 ITALY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 103 ITALY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 104 ITALY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 105 ITALY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 106 ITALY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 107 ITALY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 108 ITALY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 109 ITALY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 110 ITALY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 111 ITALY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 112 ITALY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 113 ITALY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 114 ITALY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 115 ITALY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 116 ITALY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 117 ITALY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 118 ITALY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 119 ITALY PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 120 ITALY PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 121 SPAIN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 122 SPAIN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 123 SPAIN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 124 SPAIN SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 125 SPAIN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 126 SPAIN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 127 SPAIN OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 128 SPAIN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 129 SPAIN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 130 SPAIN PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 131 SPAIN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 132 SPAIN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 133 SPAIN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 134 SPAIN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 135 SPAIN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 136 SPAIN PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 137 SPAIN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 138 SPAIN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 139 SPAIN PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 140 SPAIN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 141 SPAIN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 142 SPAIN PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 143 SPAIN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 144 SPAIN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 145 SPAIN PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 146 SPAIN PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 147 SPAIN PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 148 RUSSIA PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 149 RUSSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 150 RUSSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 151 RUSSIA SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 152 RUSSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 153 RUSSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 154 RUSSIA OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 155 RUSSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 156 RUSSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 157 RUSSIA PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 158 RUSSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 159 RUSSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 160 RUSSIA PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 161 RUSSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 162 RUSSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 163 RUSSIA PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 164 RUSSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 165 RUSSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 166 RUSSIA PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 167 RUSSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 168 RUSSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 169 RUSSIA PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 170 RUSSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 171 RUSSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 172 RUSSIA PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 173 RUSSIA PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 174 RUSSIA PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 175 TURKEY PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 176 TURKEY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 177 TURKEY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 178 TURKEY SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 179 TURKEY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 180 TURKEY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 181 TURKEY OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 182 TURKEY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 183 TURKEY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 184 TURKEY PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 185 TURKEY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 186 TURKEY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 187 TURKEY PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 188 TURKEY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 189 TURKEY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 190 TURKEY PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 191 TURKEY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 192 TURKEY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 193 TURKEY PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 194 TURKEY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 195 TURKEY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 196 TURKEY PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 197 TURKEY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 198 TURKEY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 199 TURKEY PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 200 TURKEY PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 201 TURKEY PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 202 BELGIUM PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 203 BELGIUM SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 204 BELGIUM SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 205 BELGIUM SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 206 BELGIUM OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 207 BELGIUM OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 208 BELGIUM OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 209 BELGIUM PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 210 BELGIUM PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 211 BELGIUM PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 212 BELGIUM PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 213 BELGIUM PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 214 BELGIUM PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 215 BELGIUM PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 216 BELGIUM PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 217 BELGIUM PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 218 BELGIUM PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 219 BELGIUM PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 220 BELGIUM PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 221 BELGIUM PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 222 BELGIUM PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 223 BELGIUM PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 224 BELGIUM PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 225 BELGIUM PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 226 BELGIUM PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 227 BELGIUM PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 228 BELGIUM PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 229 NETHERLANDS PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 230 NETHERLANDS SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 231 NETHERLANDS SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 232 NETHERLANDS SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 233 NETHERLANDS OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 234 NETHERLANDS OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 235 NETHERLANDS OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 236 NETHERLANDS PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 237 NETHERLANDS PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 238 NETHERLANDS PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 239 NETHERLANDS PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 240 NETHERLANDS PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 241 NETHERLANDS PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 242 NETHERLANDS PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 243 NETHERLANDS PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 244 NETHERLANDS PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 245 NETHERLANDS PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 246 NETHERLANDS PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 247 NETHERLANDS PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 248 NETHERLANDS PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 249 NETHERLANDS PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 250 NETHERLANDS PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 251 NETHERLANDS PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 252 NETHERLANDS PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 253 NETHERLANDS PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 254 NETHERLANDS PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 255 NETHERLANDS PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 256 SWITZERLAND PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 257 SWITZERLAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 258 SWITZERLAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 259 SWITZERLAND SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 260 SWITZERLAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 261 SWITZERLAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 262 SWITZERLAND OPTICAL IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 263 SWITZERLAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
TABLE 264 SWITZERLAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (VOLUME)
TABLE 265 SWITZERLAND PRECLINICAL NUCLEAR IMAGING SYSTEMS IN PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 266 SWITZERLAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 267 SWITZERLAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 268 SWITZERLAND PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 269 SWITZERLAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 270 SWITZERLAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 271 SWITZERLAND PRECLINICAL OPTICAL IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 272 SWITZERLAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 273 SWITZERLAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 274 SWITZERLAND PRECLINICAL NUCLEAR IMAGING REAGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 275 SWITZERLAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 276 SWITZERLAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 277 SWITZERLAND PRECLINICAL MRI CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 278 SWITZERLAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (USD THOUSAND)
TABLE 279 SWITZERLAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (VOLUME)
TABLE 280 SWITZERLAND PRECLINICAL CT CONTRAST AGENTS IN PRECLINICAL IMAGING MARKET, BY REAGENTS, 2021-2030 (ASP)
TABLE 281 SWITZERLAND PRECLINICAL IMAGING MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND)
TABLE 282 SWITZERLAND PRECLINICAL IMAGING MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 283 REST OF EUROPE PRECLINICAL IMAGING MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND)
Lista de Figura
FIGURE 1 EUROPE PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 2 EUROPE PRECLINICAL IMAGING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PRECLINICAL IMAGING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PRECLINICAL IMAGING MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE PRECLINICAL IMAGING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PRECLINICAL IMAGING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PRECLINICAL IMAGING MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 EUROPE PRECLINICAL IMAGING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE PRECLINICAL IMAGING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE PRECLINICAL IMAGING MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF CHRONIC DISORDER AND ADVANCEMENTS IN IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE PRECLINICAL IMAGING MARKET FROM 2023 TO 2030
FIGURE 12 SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRECLINICAL MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PRECLINICAL IMAGING MARKET
FIGURE 14 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, 2022
FIGURE 15 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 16 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 17 EUROPE PRECLINICAL IMAGING MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, 2022
FIGURE 19 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, 2023-2030 (USD THOUSANDS)
FIGURE 20 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, CAGR (2023-2030)
FIGURE 21 EUROPE PRECLINICAL IMAGING MARKET: BY REAGENTS, LIFELINE CURVE
FIGURE 22 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, 2022
FIGURE 23 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, 2023-2030 (USD THOUSANDS)
FIGURE 24 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 25 EUROPE PRECLINICAL IMAGING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, 2022
FIGURE 27 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE PRECLINICAL IMAGING MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE PRECLINICAL IMAGING MARKET: SNAPSHOT (2022)
FIGURE 31 EUROPE PRECLINICAL IMAGING MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
